Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsSunpharmaceuticalindustries

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Prefer Ashok Leyland, GSK Cons, Sun Pharma: Ajay Bodke

      Ajay Bodke of Prabhudas Lilladher is of the view that one can look at Ashok Leyland, Tata Motors, GlaxoSmithKline Consumer Healthcare, Britannia Industries and Sun Pharma.

    • Prefer L&T, Axis Bank, Infosys: Gaurang Shah

      Gaurang Shah of Geojit BNP Paribas is of the view that one may prefer Sun Pharmaceutical, Larsen & Toubro (L&T), Infosys and Tata Motors.

    • Expect 20% upside in Sun Pharma, says Pankaj Sharma

      Pankaj Sharma, Head-Equities at Equirus Securities expects 20 percent upside in Sun Pharma.

    • Like Alembic Pharma, buy on dips: Mehraboon Irani

      Mehraboon Irani of Nirmal Bang Securities likes Alembic Pharma and recommends buying the stock on dips.

    • Buy Dr Reddy's Labs, Reliance Industries; sell Colgate: Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that one can buy Dr Reddy's Labs and Reliance Industries and advises selling Colgate Palmolive.

    • Buy Hexaware, Arvind, Sun Pharma: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that one may buy Hexaware, Arvind and Sun Pharma.

    • Pick Asian Paints, Britannia; like YES Bank, HDFC Bank: Emkay

      Dhananjay Sinha - Head, Institutional Research at Emkay Global Financial Services is of the view that one can pick Asian Paints, Britannia Industries and Marico and likes YES Bank, HDFC Bank and HCL Technologies.

    • Buy Sun Pharma 980 Call, RComm 55 Call: VK Sharma

      VK Sharma of HDFC Securities recommends buying Sun Pharma 980 Call and Reliance Communications 55 Call.

    • Buy Sun Pharma; short ACC: Rajat Bose

      Rajat Bose of rajatkbose.com recommends buying Sun Pharma and advises shorting ACC.

    • Buy Sun Pharma, sell banking stocks: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com is of the view that one can buy Sun Pharma and feels that all banking stocks are sell ideas.

    • Buy Sun Pharma, says CA Rudramurthy BV

      CA Rudramurthy BV of Vachana Investments is of the view that one may buy Sun Pharmaceutical Industries.

    • Buy Lupin, BEML; avoid IT stocks: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy Lupin, Sun Pharmaceutical and BEML.

    • Sun Pharmaceutical may test Rs 930-945: Pankaj Jain

      Pankaj Jain of SW Capital feels that Sun Pharmaceutical may test Rs 930-945.

    • Buy Cadila Healthcare; pharma may outperform Nifty: Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Cadila Healthcare and feels that pharma may outperform Nifty.

    • Buy Sun Pharma at around Rs 820-850, JSW Steel: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying Sun Pharma at around Rs 820-850 and also JSW Steel.

    • Buy Bajaj Auto, Sun Pharma: Yogesh Mehta

      Yogesh Mehta of Motilal Oswal Securities recommends buying Bajaj Auto and Sun Pharma.

    • Buy UltraTech, Biocon, CESC; sell Engineers India, OBC: Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying UltraTech Cement, Biocon and CESC and advises selling Engineers India and OBC.

    • Super Six: Top chart picks for today

      Sameet Chavan of Angel Broking is of the view that one may buy UltraTech Cement with a target of Rs 3070.

    • See upside in Sun Pharma: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may see upside in Sun Pharma.

    • Buy BEL, NBCC, GSFC, Sun Pharma: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying BEL, NBCC, GSFC and Sun Pharma.

    • Pick Arvind, Lupin: Gaurang Shah

      Gaurang Shah of Geojit BNP Paribas is of the view that one may pick Arvind, Lupin or HCL Technologies.

    • Buy Tata Motors, advises Deven Choksey

      Deven Choksey of KRChoksey Investment Managers recommends buying Tata Motors.

    • Buy Sun Pharma, JSW Energy, Dish TV: Manoj Murlidharan

      Manoj Murlidharan of Religare Securities is of the view that one can buy Sun Pharma, JSW Energy and Dish TV.

    • Buy Sun Pharma, Cairn, Tata Steel, BoB, Torrent Pharma: Gujral

      Ashwani Gujral of ashwanigujral.com recommends buying Sun Pharma, Cairn India, Tata Steel, Bank of Baroda and Torrent Pharma.

    • Buy Sun Pharma, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Sun Pharma and advises holding the stock till Budget.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347